A101

4DMT and Arbor Biotechnologies Establish Partnership to Co-Develop and Co-Commercialize Next-Generation Genetic Medicines for CNS Diseases

Retrieved on: 
Wednesday, January 3, 2024

Arbor also has expertise in CNS biology, CNS drug development and CNS therapeutic development.

Key Points: 
  • Arbor also has expertise in CNS biology, CNS drug development and CNS therapeutic development.
  • 4DMT has utilized its platform to invent customized AAV vectors for CNS tissues, and these vectors will be deployed in the partnership.
  • “CNS disorders include some of the most devastating diseases, many of which have a genetic origin.
  • We look forward to combining our complementary technologies and capabilities to power a new generation of potential genetic medicines.

4DMT and Arbor Biotechnologies Establish Partnership to Co-Develop and Co-Commercialize Next-Generation Genetic Medicines for CNS Diseases

Retrieved on: 
Wednesday, January 3, 2024

Arbor also has expertise in CNS biology, CNS drug development and CNS therapeutic development.

Key Points: 
  • Arbor also has expertise in CNS biology, CNS drug development and CNS therapeutic development.
  • 4DMT has utilized its platform to invent customized AAV vectors for CNS tissues, and these vectors will be deployed in the partnership.
  • “CNS disorders include some of the most devastating diseases, many of which have a genetic origin.
  • We look forward to combining our complementary technologies and capabilities to power a new generation of potential genetic medicines.

4D Molecular Therapeutics Announces Updates on Clinical Pipeline and Additional Preclinical Programs

Retrieved on: 
Monday, January 9, 2023

The doses to be evaluated in DME are expected to be similar to those used in the 4D-150 wet AMD clinical trial.

Key Points: 
  • The doses to be evaluated in DME are expected to be similar to those used in the 4D-150 wet AMD clinical trial.
  • It is estimated that there are over one million individuals with GA in the United States according to published data.
  • In addition, I’m excited by the potential of 4D-175, the new preclinical product candidate utilizing the same R100 vector.
  • Cardiac clinical endpoint data (MRI, echocardiography, cardiopulmonary exercise testing [CPET] and QOL assessment) from evaluations at baseline and 12 months after treatment were assessed.